Concepedia

Publication | Closed Access

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

DOI

1.7K

Citations

24

References

2014

Year

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt,
The Lancet Oncology

References

YearCitations

Nonparametric Estimation from Incomplete Observations

Edward L. Kaplan, Paul Meier

Journal of the American Statistical Association

1958

38.7K

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer,

JNCI Journal of the National Cancer Institute

2000

15.7K

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny,

New England Journal of Medicine

2004

10.9K

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre,

New England Journal of Medicine

2009

3.8K

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol,

Journal of Clinical Oncology

2007

2.3K

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena,

New England Journal of Medicine

2013

2.2K

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi,

The Lancet Oncology

2010

2.1K

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng,

Journal of Clinical Oncology

2011

1.9K

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Eric Van Cutsem, Josep Tabernero, Radek Lakomý,

Journal of Clinical Oncology

2012

1.4K

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold,

The Lancet Oncology

2012

1.2K

Page 1